Severe acute interstitial pneumonia and gefitinib
Akira Inoue(Tohoku University Hospital), Toshihiro Nukiwa(Tohoku University), Toshiaki Kikuchi(Tohoku University), Yasuo Saijo(Ho Chi Minh City International University), Yuichiro Kimura(Tohoku University), Takuya Moriya(Kawasaki Medical School), Kazunori Gomi(Tohoku University), Makoto Maemondo(Miyagi Prefectural Hospital Organization), Masahito Ebina(Tohoku University), Yutaka Tokue(Tohoku University)
Cited by 456
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Nrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
|Cancer Cell|2012|1.4k
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2005|953
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling
|Science Translational Medicine|2011|530